Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 3/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195873 | 0.84 | BRD4 (0.47) | BRD4JAK2IKBKBCDC7CDK1 | |
| SCHEMBL4347544 | 0.83 | BRD4 (0.47) | BRD4JAK2IKBKBCDC7CDK2 | |
| SCHEMBL2196845 | 0.83 | CDC7 (0.51) | BRD4JAK2IKBKBCDC7FFAR1 | |
| SCHEMBL2196975 | 0.83 | IKBKB (0.47) | BRD4JAK2IKBKBFFAR1 | |
| SCHEMBL2198478 | 0.82 | BRD4 (0.46) | BRD4CDC7 | |
| SCHEMBL2196927 | 0.82 | CDC7 (0.54) | BRD4IKBKBCDC7CDK1MAPK8 | |
| SCHEMBL4343078 | 0.81 | BRD4 (0.60) | BRD4JAK2KDM5AKDM4CKDM5B | |
| SCHEMBL2198565 | 0.80 | BRD4 (0.50) | BRD4CDC7MAPK1MAPK8 | |
| SCHEMBL2199465 | 0.80 | BRD4 (0.43) | BRD4JAK2IKBKBCDC7CDK2 | |
| SCHEMBL2200693 | 0.80 | PARP1 (0.47) | BRD4JAK2CDC7FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116530-B1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-14 | — | — | EP | claimed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | claimed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | claimed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | claimed |
| EP-2116530-B1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | UACA, IL6, IL6ST | BRD4 497/4885JAK2 256/4885KDM5A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.